Issue 5/2021
Content (15 Articles)
Anticancer potential of metformin: focusing on gastrointestinal cancers
Mohammad rafi Khezri, Hassan Malekinejad, Naime Majidi-Zolbanin, Morteza Ghasemnejad-Berenji
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
Katharine A. Collier, Hugo Valencia, Herbert Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, Sophia G. Liva, Christopher C. Coss, Jiang Wang, Soun Khountham, Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling, Amir Mortazavi
A phase 1 trial of 4-(N-(S-penicillaminylacetyl)amino)-phenylarsonous acid (PENAO) in patients with advanced solid tumours
Sunit Sarkar, Ben Tran, Lisa Horvath, Michael Lam, Peter Savas, Peter Grimison, James R. Whittle, James C. Kuo, Nicole Signal, David Edmonds, Philip Hogg, Danny Rischin, Jayesh Desai, Anne Hamilton
Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
Reza Khosravan, Steven G. DuBois, Katherine Janeway, Erjian Wang
Evaluating clinical impact of a shortened infusion duration for ramucirumab: a model-based approach
Ling Gao, Yiu-Keung Lau, Ran Wei, Lisa O’Brien, Amanda Long, Yongzhe Piao, Paolo Abada
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway
Xianglan Yi, Liping Lou, Jun Wang, Jing Xiong, Sheng Zhou
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population
Jatta Saarenheimo, Nesna Wahid, Natalja Eigeliene, Ravichandra Ravi, Gajja S. Salomons, Matilde Fernandez Ojeda, Raymon Vijzelaar, Antti Jekunen, André B. P. van Kuilenburg
Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
Keiichiro Ishibashi, Toru Aoyama, Masahito Kotaka, Hironaga Satake, Yasushi Tsuji, Masato Kataoka, Masato Nakamura, Naoki Nagata, Junichi Sakamoto, Koji Oba, Hideyuki Mishima
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
Filipa Lynce, James T. Williams, Meredith M. Regan, Craig A. Bunnell, Rachel A. Freedman, Sara M. Tolaney, Wendy Y. Chen, Erica L. Mayer, Ann H. Partridge, Eric P. Winer, Beth Overmoyer
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine
Duo Liu, Xuehua Li, Xiang Li, Huiqi Wang, Mei Dong
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
Chao Li, Lowell Hart, Taofeek K. Owonikoko, Raid Aljumaily, Caio Max Rocha Lima, Paul R. Conkling, Roy Timothy Webb, Robert M. Jotte, Steven Schuster, William J. Edenfield, Deborah A. Smith, Mark Sale, Patrick J. Roberts, Rajesh K. Malik, Jessica A. Sorrentino
Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis
Yang Liu, Yongde Cao, Leting Xiao, Haijiang Wang
Comparison of a thymine challenge test and endogenous uracil–dihydrouracil levels for assessment of fluoropyrimidine toxicity risk
Kathryn E. Burns, Ottiniel Chavani, Soo Hee Jeong, John A. Duley, David Porter, Michael Findlay, R. Matthew Strother, Nuala A. Helsby
Detecting DPD deficiency: when perfect is the enemy of good
Joseph Ciccolini, Gérard Milano, Henk-Jan Guchelaar
Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR‑181 level
Anjing Gong, Na Ge, Weicheng Yao, Luxiang Lu, Hui Liang